Omnimodus Elixir Kft. — Clinical Trial Site

16 Registered trials

4 Currently recruiting

Organisation

Omnimodus Elixir Kft.

Location

Mosonmagyarovar, Hungary

Identifier

ORG-100045890

Address

Soproni Ut 64, 9300, Hungary

Departments

n/a
NA
Omnimodus Elixír Szolgáltató Kft.
Priv
private clinic
Private site
Pulmonology Department

Clinical trials at this site (16)

Search interface

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1) Pending

2025-521950-41-00 severe uncontrolled asthma 5
Long-term safety and efficacy evaluation of lunsekimig (SAR443765) in adult participants with moderate-to-severe asthma. Recruiting

2025-522896-27-00 Asthma 4 2026-05-11
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-to-Severe Asthma Recruiting

2024-517866-40-00 Moderate-to-severe Asthma 4 2025-09-29
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmona… Recruiting

2024-517457-27-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2025-06-04
Study of lunsekimig (SAR443765) compared with placebo in adults with high-risk asthma Recruiting

2024-513959-33-00 Asthma 4 2025-05-13
A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended

2023-505435-12-00 Asthma 5 2024-06-04
A study to investigate long-term safety and tolerability of itepekimab in participants with COPD Ended

2023-508085-15-00 Chronic Obstructive Pulmonary Disease 5 2024-05-15
A Phase 3, 52-Week, Randomized, Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory or Une… Ended

2024-513460-26-00 Refractory Chronic Cough, Including Unexplained Chronic 5 2023-03-29
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients with Uncontrolled Moderate to Sev… Ended

2024-513423-16-00 Asthma 6 2022-08-25
A study to investigate the effect on lung function of an approved COPD treatment (BGF, with HFA propellant) compared to BGF formulated with… Ended

2023-506565-57-00 Moderate to Severe Chronic Obstructive Pulmonary Diseas 5 2024-06-21
"Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended

2023-505543-39-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-02-12
A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease Ended

2022-502234-70-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2023-07-14
Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended

2022-501063-41-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2023-04-20
Dose ranging study of amlitelimab in adult participants with moderate-to-severe asthma Ended

2024-510641-33-00 Asthma 4 2023-01-17
Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended

2023-503571-19-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2022-01-20
Study to assess the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab in chronic obstructive pulmonary disease (COPD) (AER… Ended

2024-512013-41-00 Chronic Obstructive Pulmonary Disease 5 2021-03-22